If the reason for the recent circa 20% slide is this guidance, it sure took its time to manifest. Then again, it looks like almost every company that is not tech/healthcare with astronomical P/E is being sold off gradually since the new FY.
We may retest the sub 4 April lows in the coming days, which should be an excellent opportunity to load up on LYL.
News: LYL Lycopodium Revises Guidance Of NPAT In Order Of $11.5 Mln For FY Ending 30 June, page-2
Add LYL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.75 |
Change
0.050(0.36%) |
Mkt cap ! $546.4M | |||
| Open | High | Low | Value | Volume |
| $13.67 | $13.82 | $13.63 | $252.1K | 18.37K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 56 | $13.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.75 | 116 | 1 |
View Market Depth
| Last trade - 12.00pm 23/07/2024 (20 minute delay) ? |
| LYL (ASX) Chart |